Carfilzomib, Dexamethasone, and Daratumumab Myeloma Treatment Alternative

February 1, 2021

Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, talks about the use of carfilzomib, dexamethasone, and daratumumab as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.

Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, a consultant clinical and laboratory hematologist at St. Vincent’s Hospital in East Melbourne, Australia talks about the use of carfilzomib (Kyprolis), dexamethasone, and daratumumab (Darzalex) as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.

Lenalidomide and bortezomib are often used to treat patients with newly-diagnosed multiple myeloma. However, many patients progress while on these agents or discontinue them due to toxicity. According to Quach, not all jurisdictions are able to afford the higher cost combination of carfilzomib and lenalidomide. Therefore, a more affordable yet equally effective alternative must be found.

The study, which was presented at the 62nd American Society of Hematology Meeting and Exposition, is a collaboration between the Asian Myeloma Network and the Australian Leukemia Myeloma Group.